Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) are a group of rare diseases that cause serious morbidity and high mortality. There is growing consensus that the presently employed histopathology-based classification of FSGS/MCD is limited because it is not based on an understanding of the molecular basis of these diseases, and because it does not well predict the heterogeneous natural history or response to therapy of those affected. Given these shortcomings, it is not surprising that our therapeutic approach to these diseases is imperfect. We propose that several major barriers must be overcome before more effective interventional studies of primary non-inflammatory glomerular disease can be conducted. Among these barriers is the absence of specific biomarkers of glomerular disease that would allow refined, biologically relevant sub-classification of glomerular disease histopathology useful for defining subject inclusion and exclusion criteria in clinical studies. Such disease sub-classification might overcome the effects of study population heterogeneity that likely have complicated interpretation of past studies of these glomerular diseases. New glomerular disease biomarkers might also predict disease natural history, allow proper selection of and prediction of response to specific therapeutic intervention, allow early detection of disease, or provide indicators of disease activity. Importantly, a robust investigative infrastructure is presently lacking that would facilitate collection, cultivation, and access to human biological material and associated clinical data necessary for biomarker identification, for the identification of clinically relevant study endpoints, and for conducting pilot clinical studies that would advance the care of FSGS/MCD patients. This application proposes a collaborative prospective observational cohort study of patients who present with histopathology characteristic of FSGS/MCD. After collecting 250 patients with this kidney biopsy characteristic, and their associated clinical data, kidney tissue, blood, and urine, the initial goals of the FSGS/MCD Cohort study are: (a) to develop and use a combination of molecular phenotypes, quantifiable histological parameters, and discrete clinical features to predict clinical outcomes;and (b) to classify patients according to their molecular phenotype into discrete subgroups. These studies hold out the promise to the clinician of being able to predict the natural history of FSGS/MCD.

Public Health Relevance

FSGS histopathology is a common presentation of a group of rare diseases that cause serious morbidity and high mortality, generating enormous individual and societal economic burden. This prospective observational cohort study will provide a readily accessible research and education resource that will significantly advance our ability to study, classify, characterize, diagnose, and treat non-inflammatory glomerular diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54DK083912-05
Application #
8538362
Study Section
Special Emphasis Panel (ZRG1-HOP-Y)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
5
Fiscal Year
2013
Total Cost
$257,326
Indirect Cost
$57,823
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Spinale, Joann M; Mariani, Laura H; Kapoor, Shiv et al. (2015) A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease. Kidney Int 87:564-74
Kerlin, Bryce A; Smoyer, William E; Tsai, James et al. (2015) Healthcare burden of venous thromboembolism in childhood chronic renal diseases. Pediatr Nephrol 30:829-37
Sampson, Matthew G; Hodgin, Jeffrey B; Kretzler, Matthias (2015) Defining nephrotic syndrome from an integrative genomics perspective. Pediatr Nephrol 30:51-63; quiz 59
Moeller, Sina; Canetta, Pietro A; Taylor, Annette K et al. (2014) Lack of serologic evidence to link IgA nephropathy with celiac disease or immune reactivity to gluten. PLoS One 9:e94677
O'Toole, John F; Sedor, John R (2014) Kidney disease: new technologies translate mechanisms to cure. J Clin Invest 124:2294-8
Canetta, Pietro A; Kiryluk, Krzysztof; Appel, Gerald B (2014) Glomerular diseases: emerging tests and therapies for IgA nephropathy. Clin J Am Soc Nephrol 9:617-25
Gadegbeku, Crystal A; Gipson, Debbie S; Holzman, Lawrence B et al. (2013) Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 83:749-56
Hogan, Marie C; Johnson, Kenneth L; Zenka, Roman M et al. (2013) Subfractionation, characterization, and in-depth proteomic analysis of glomerular membrane vesicles in human urine. Kidney Int :
Burnworth, Bettina; Pippin, Jeff; Karna, Prasanthi et al. (2012) SSeCKS sequesters cyclin D1 in glomerular parietal epithelial cells and influences proliferative injury in the glomerulus. Lab Invest 92:499-510
Keller, Benjamin J; Martini, Sebastian; Sedor, John R et al. (2012) A systems view of genetics in chronic kidney disease. Kidney Int 81:14-21

Showing the most recent 10 out of 14 publications